ArticleCellular & molecular biology letters2025
Crosstalk between endothelial cells and osteoblasts stimulates ALP via Notch signaling and RANKL/OPG ratio independently of Notch signaling in vitro.
Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Vascularized bone organoids: current advances and a biomimetic platform for osteonecrosis of the femoral head.Bone research · 2026Review
- Advancing Biomaterials Evaluation: A Human Quadruple Bone Cell Culture Reveals Molybdenum-Driven Pro-Osteogenic and Anti-osteoclastogenic Responses.ACS applied materials & interfaces · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundBone remodeling requires a complex interplay between osteogenesis and angiogenesis, orchestrated by yet not fully understood intricate signaling pathways in osteoblasts and endothelial cells.
methodsIn the present study, co-cultures of primary human osteoblasts and human umbilical vein endothelial cells (HUVEC) were compared with osteoblast cultures treated with dexamethasone (Dex), vascular endothelial growth factor (VEGF), their combination, or VEGF in the presence of Notch inhibitor N-[N-(3,5-difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester (DAPT). Cellular behavior was analyzed at morphological, gene expression, and protein levels to identify key regulators in the interplay between osteoblasts and endothelial cells.
resultsDex and VEGF additively increased alkaline phosphatase (ALP) in osteoblast-HUVEC co-cultures, but not in osteoblast cultures. Furthermore, Dex reduced the receptor activator of nuclear factor κB ligand/osteoprotegerin (RANKL/OPG) ratio in osteoblasts. This effect was reversed in the presence of VEGF, but only in co-culture, indicating a direct action of endothelial cells, rather than VEGF itself, in stimulating RANKL and reducing OPG in osteoblasts. In addition, Notch signaling, specifically NOTCH1 and DLL4, was induced in response to VEGF solely in co-cultures. The presence of Notch inhibitor DAPT suppressed VEGF-induced stimulation of ALP but not RANKL/OPG ratio.
conclusionsOur findings provide novel evidence for the significant role of endothelial cells in bone remodeling, specifically in regulating ALP expression and activity of osteoblasts via the Notch signaling pathway and RANKL/OPG ratio independent of Notch. This study underscores the applicability and significance of multicellular tissue models for studying bone turnover processes in vitro, thereby reducing the reliance on animal testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.